Heron Therapeutics
HRTX59
$2.05arrow_drop_up8.46%$0.16
Penny Stock
HRTX59
$2.05
arrow_drop_up8.46%Performance History
| Key Stats | |
|---|---|
| Open | $2.09 |
| Prev. Close | $2.06 |
| EPS | -0.25 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $312.43M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.94 | 2.09 |
| 52 Week Range | 0.50 | 3.93 |
| Ratios | |
|---|---|
| EPS | -0.25 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Heron Therapeutics (HRTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Craig Alexander Collard
- Headquarters
- San Diego
- Employees
- 203
- Exchange
- NASDAQ
Keep an eye on Heron Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Heron Therapeutics 's (HRTX) price per share?
The current price per share for Heron Therapeutics (HRTX) is $2.05. The stock has seen a price change of $0.16 recently, indicating a 8.47% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Heron Therapeutics (HRTX)?
For Heron Therapeutics (HRTX), the 52-week high is $3.93, which is 91.71% from the current price. The 52-week low is $0.5, the current price is 310% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Heron Therapeutics (HRTX) a growth stock?
Heron Therapeutics (HRTX) has shown an average price growth of 0.41% over the past three years. It has received a score of 13 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Heron Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Heron Therapeutics (HRTX) stock price performance year to date (YTD)?
As of the latest data, Heron Therapeutics (HRTX) has a year-to-date price change of 8.47%. Over the past month, the stock has experienced a price change of 3.54%. Over the last three months, the change has been -38.44%. Over the past six months, the figure is -25.18%. Looking at a longer horizon, the five-year price change stands at -89.12%.
help
Is Heron Therapeutics (HRTX) a profitable company?
Heron Therapeutics (HRTX) has a net income of -$110.56M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 48.75% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -17.89% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $127.04M, with a revenue growth rate of 17.99%, providing insight into the company's sales performance and growth. The gross profit is $61.94M. Operating income is noted at -$110.62M. Furthermore, the EBITDA is -$26.02M.
help
What is the market capitalization of Heron Therapeutics (HRTX)?
Heron Therapeutics (HRTX) has a market capitalization of $310.92M. The average daily trading volume is 2.67M, indicating the stock's liquidity and investor engagement.
News
CHEMOTHERAPY
NAUSEA
VOMITING
CANCER
TREATMENT
MARKET
9/17/2024Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
7/2/2024
Merck (MRK) Gets Exclusive Rights to Opevesostat From Partner
7/1/2024
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
6/27/2024
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
6/26/2024
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
6/25/2024
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?